Yuxiang Wen1, Murad A Jabir1, Michael Keating1, Alison R Althans1, Justin T Brady2, Bradley J Champagne1, Conor P Delaney3, Scott R Steele1. 1. Department of Colorectal Surgery, University Hospitals Cleveland Medical Center, 11100 Euclid Avenue, Cleveland, OH, 44016, USA. 2. Department of Colorectal Surgery, University Hospitals Cleveland Medical Center, 11100 Euclid Avenue, Cleveland, OH, 44016, USA. Justin.Brady@UHhospitals.org. 3. Digestive Disease and Surgery Institute, Cleveland Clinic, Cleveland, OH, USA.
Abstract
BACKGROUND: Postoperative ileus (POI) is a major cause of morbidity, increased length of stay (LOS) and hospital cost after colorectal surgery. Alvimopan is a µ-opioid antagonist used to accelerate upper and lower gastrointestinal function after bowel resection. We hypothesized that alvimopan would reduce LOS in patients undergoing colorectal resection with stoma, a situation that has not been evaluated. METHODS: A retrospective review (2010-2015) identified 58 patients who underwent colorectal resection for benign or malignant disease with stoma creation and received alvimopan. They were case-matched to 58 non-alvimopan patients based on age, BMI, baseline comorbidities, stoma type created and surgical approach. We compared overall LOS, incidence of POI and other postoperative complications. RESULTS: There were equal numbers of laparoscopic (N = 18) and open resections (N = 40) in the alvimopan group and non-alvimopan group. There were also equal numbers of patients with an ileostomy (N = 37) or colostomy (N = 21) in each group. Overall, 41 patients underwent resection for malignant disease in the alvimopan group compared to 37 in the non-alvimopan group. There was a significant reduction in median LOS overall (alvimopan 5 (4-7) versus control 6 (4.75-9.25) days, P = 0.03). While the 6-day median LOS was similar for patients undergoing ileostomy creation (P = 0.25), alvimopan patients had a 3-day decreased median LOS that approached statistical significance (P = 0.06). The overall 30-day complication rate was higher in the control group (41.4 vs. 51.7%, P = 0.26), but the readmission rate within 30 days was higher in the alvimopan group (19 vs. 13.8%, P = 0.45). Neither of these differences reached statistically significance. CONCLUSION: The use of alvimopan in patients undergoing colorectal resection with stoma is associated with a significantly shorter LOS, but the increased readmission rate warrants further study. Based on these data, alvimopan should be evaluated in a controlled setting for patients undergoing colorectal resection with colostomy creation.
BACKGROUND: Postoperative ileus (POI) is a major cause of morbidity, increased length of stay (LOS) and hospital cost after colorectal surgery. Alvimopan is a µ-opioid antagonist used to accelerate upper and lower gastrointestinal function after bowel resection. We hypothesized that alvimopan would reduce LOS in patients undergoing colorectal resection with stoma, a situation that has not been evaluated. METHODS: A retrospective review (2010-2015) identified 58 patients who underwent colorectal resection for benign or malignant disease with stoma creation and received alvimopan. They were case-matched to 58 non-alvimopanpatients based on age, BMI, baseline comorbidities, stoma type created and surgical approach. We compared overall LOS, incidence of POI and other postoperative complications. RESULTS: There were equal numbers of laparoscopic (N = 18) and open resections (N = 40) in the alvimopan group and non-alvimopan group. There were also equal numbers of patients with an ileostomy (N = 37) or colostomy (N = 21) in each group. Overall, 41 patients underwent resection for malignant disease in the alvimopan group compared to 37 in the non-alvimopan group. There was a significant reduction in median LOS overall (alvimopan 5 (4-7) versus control 6 (4.75-9.25) days, P = 0.03). While the 6-day median LOS was similar for patients undergoing ileostomy creation (P = 0.25), alvimopanpatients had a 3-day decreased median LOS that approached statistical significance (P = 0.06). The overall 30-day complication rate was higher in the control group (41.4 vs. 51.7%, P = 0.26), but the readmission rate within 30 days was higher in the alvimopan group (19 vs. 13.8%, P = 0.45). Neither of these differences reached statistically significance. CONCLUSION: The use of alvimopan in patients undergoing colorectal resection with stoma is associated with a significantly shorter LOS, but the increased readmission rate warrants further study. Based on these data, alvimopan should be evaluated in a controlled setting for patients undergoing colorectal resection with colostomy creation.
Authors: P M King; J M Blazeby; P Ewings; P J Franks; R J Longman; A H Kendrick; R M Kipling; R H Kennedy Journal: Br J Surg Date: 2006-03 Impact factor: 6.939
Authors: Ian M Paquette; Patrick Solan; Janice F Rafferty; Martha A Ferguson; Bradley R Davis Journal: Dis Colon Rectum Date: 2013-08 Impact factor: 4.585
Authors: Conor P Delaney; Bruce G Wolff; Eugene R Viscusi; Anthony J Senagore; John G Fort; Wei Du; Lee Techner; Bruce Wallin Journal: Ann Surg Date: 2007-03 Impact factor: 12.969
Authors: Evangelos Messaris; Rishabh Sehgal; Susan Deiling; Walter A Koltun; David Stewart; Kevin McKenna; Lisa S Poritz Journal: Dis Colon Rectum Date: 2012-02 Impact factor: 4.585
Authors: Kirk Ludwig; Eugene R Viscusi; Bruce G Wolff; Conor P Delaney; Anthony Senagore; Lee Techner Journal: World J Surg Date: 2010-09 Impact factor: 3.352
Authors: Kirk Ludwig; Warren E Enker; Conor P Delaney; Bruce G Wolff; Wei Du; John G Fort; Maryann Cherubini; James Cucinotta; Lee Techner Journal: Arch Surg Date: 2008-11
Authors: Jean F Hamel; Charles Sabbagh; Arnaud Alves; Jean M Regimbeau; Timothée Vignaud; Aurélien Venara Journal: Sci Rep Date: 2021-04-01 Impact factor: 4.379
Authors: I Vogel; M Shinkwin; S L van der Storm; J Torkington; J A Cornish; P J Tanis; R Hompes; W A Bemelman Journal: Tech Coloproctol Date: 2022-02-22 Impact factor: 3.699